Cell culture media for recombinant protein expression in chinese hamster ovary (CHO) cells: history, key components, and optimization strategies
Abstract
The culture of Chinese Hamster Ovary (CHO) cells for modern industrial applications, such as expression of recombinant proteins, requires media that support growth and production. Such media must support high viable cell densities while also stimulating the synthesis and extracellular transport of biologic products. Early media development efforts in this area yielded basic formulations to sustain growth, viability, and cellular function, albeit comprising animal sourced components, and complex constituents used in batch culture mode. Subsequent improvements included the development of serum‐free and chemically defined (CD) media, the identification of critical nutrients, growth factors, and potentially inhibitory or toxic cellular metabolites, and the use of fed‐batch and perfusion culture techniques to optimize nutrient delivery while minimizing accumulation of unwanted waste products. This review is comprised of sections covering milestones in the evolution of mammalian cell culture media, nutrient composition and formulation requirements, optimization strategies, consistency and scalability of powder and liquid media preparation for industrial applications, and key recent advances driving progress in CHO cell culture medium design and development. © 2018 American Institute of Chemical Engineers Biotechnol. Prog ., 34:1407–1426, 2018
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Fully defined formulations remain challenging to implement for many systems.
“However, fully defined formulations remain challenging to implement for many systems (Galbraith et al., 2018; Ritacco et al., 2018; van der Valk et al., 2018).”
From Challenges and solutions in transitioning to animal-free standards: a comprehensive analysis of components in human cell-based developmental neurotoxicity assays (2026) · cites this paper as Ritacco et al., 2018
Cites
Lao, M.-S., & Toth, D. (1997) · Biotechnology Progress · doi:10.1021/bp9602360 · Cited by 268 · see citing works
Scale‐up analysis for a CHO cell culture process in large‐scale bioreactors
Xing, Z., Kenty, B. M., Li, Z. J., & Lee, S. S. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22287 · Cited by 228 · see citing works
Jiang, Z., & Sharfstein, S. T. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21726 · Cited by 118 · see citing works
Metabolic responses of CHO cells to limitation of key amino acids
Duarte, T. M., Carinhas, N., Barreiro, L. C., Carrondo, M. J. T., Alves, P. M., & Teixeira, A. P. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25266 · Cited by 110 · see citing works
Stolfa, G., Smonskey, M. T., Boniface, R., Hachmann, A., Gulde, P., Joshi, A. D., Pierce, A. P., Jacobia, S. J., & Campbell, A. (2018) · Biotechnology Journal · doi:10.1002/biot.201700227 · Cited by 97 · see citing works
Addition of Valproic Acid to CHO Cell Fed-Batch Cultures Improves Monoclonal Antibody Titers
Yang, W. C., Lu, J., Nguyen, N. B., Zhang, A., Healy, N. V., Kshirsagar, R., Ryll, T., & Huang, Y.-M. (2014) · Molecular Biotechnology · doi:10.1007/s12033-013-9725-x · Cited by 89 · see citing works
Reversion of a Chinese Hamster Cell Auxotrophic Mutant
Chasin, L. A., Feldman, A., Konstam, M., & Urlaub, G. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.3.718 · Cited by 81 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Ha, T. K., Kim, D., Kim, C. L., Grav, L. M., & Lee, G. M. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107831 · Cited by 74 · see citing works
Current advances in the algae-made biopharmaceuticals field
Rosales-Mendoza, S., Solís-Andrade, K. I., Márquez-Escobar, V. A., González-Ortega, O., & Bañuelos-Hernandez, B. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1739643 · Cited by 55 · see citing works
Pérez-Rodriguez, S., Ramírez-Lira, M. D. J., Trujillo-Roldán, M. A., & Valdez-Cruz, N. A. (2020) · Bioengineered · doi:10.1080/21655979.2020.1744266 · Cited by 32 · see citing works
Spänle, J. V., Haiber, L. M., & Seeger, B. (2026) · Frontiers in Toxicology · doi:10.3389/ftox.2026.1800157 · Cited by 1 · see citing works
- Authors
- Ritacco, F. V., Wu, Y., & Khetan, A.
- Affiliations
- Biologics Process Development Bristol‐Myers Squibb Pennington New Jersey United States
- ORCID
- Ritacco, Frank V.
- Venue
- Biotechnology Progress
- Publisher
- Wiley
- Published
- 2018-10-05
- Volume
- 34
- Issue
- 6
- Pages
- 1407-1426
- ISSN
- 8756-7938
- 1520-6033
- Cited by
- 263
- References
- 7
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
